Preliminary Guidelines for the Use of IVIg during COVID-19

Abstract

Infection with the severe acute respiratory syndrome novel type-2 novel coronavirus (SARS-CoV-2) responsible for the 2019 coronavirus disease (CO-VID-19) shows a highly heterogeneous clinical presentation and age affliction in children and adults, ranging from asymptomatic or mild disease to severe involvement, with potentially fatal respiratory failure and multiple organ dysfunction. As susceptibility to severe COVID-19 depends upon comorbid factors including immune competence, optimizing the latter through low-dose supplementation or high dose treatment with immune globulin therapy in those with primary immune deficiency and post-infectious immune sequelae of SARS-CoV-2 and existing autoimmune disorders is essential. There are no existing guidelines hence; this paper provides a framework for considering preliminary guidelines for the use of immune globulin therapy during COVID-19.

Immune-based therapeutic approaches in COVID-19

“…Low dose IVIG is indicated in unvaccinated patients with autoimmune disorders or primary and secondary immunodeficiencies for protection against exposure to the virus. IVIG is also helpful in neurological disorders as a result of COVID-19’s inflammatory sequelae, including cognitive dysfunction, neuralgia, insomnia, and autonomic nervous system involvement [70] .…”